At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLNO Soleno Therapeutics
Market Closed 12-12 16:00:00 EST
52.00
+2.51
+5.07%
盘后52.00
+0.000.00%
18:29 EST
High52.79Low49.10Vol1.45M
Open49.80D1 Closing49.49Amplitude7.46%
Mkt Cap2.79BTradable Cap2.33BTotal Shares53.71M
T/O73.74MT/O Rate3.23%Tradable Shares44.87M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Soleno Therapeutics (SLNO) Valuation Check After Wolfe’s Bullish Call Challenges Short-Seller Concerns
Simply Wall St.  ·  12-04
Soleno Therapeutics (SLNO) Valuation Check After Wolfe’s Bullish Call Challenges Short-Seller Concerns
Press Release: Soleno Therapeutics Announces the Passing of Board Member William G. Harris
Dow Jones  ·  12-04
Press Release: Soleno Therapeutics Announces the Passing of Board Member William G. Harris
How Does Wolfe Research’s Support Shape Soleno Therapeutics’ (SLNO) Credibility Amid Heightened Scrutiny?
Simply Wall St.  ·  12-02
How Does Wolfe Research’s Support Shape Soleno Therapeutics’ (SLNO) Credibility Amid Heightened Scrutiny?
Soleno Therapeutics Files Initial Beneficial Ownership Statement for Chief Business Officer Kevin Norrett
Reuters  ·  11-20
Soleno Therapeutics Files Initial Beneficial Ownership Statement for Chief Business Officer Kevin Norrett
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement
Reuters  ·  11-20
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement
Soleno Therapeutics Initiated at Outperform by Wolfe Research
Dow Jones  ·  11-19
Soleno Therapeutics Initiated at Outperform by Wolfe Research
Soleno Therapeutics Unveils Corporate Presentation Highlighting VYKAT XR Launch for Prader-Willi Syndrome Hyperphagia
Reuters  ·  11-19
Soleno Therapeutics Unveils Corporate Presentation Highlighting VYKAT XR Launch for Prader-Willi Syndrome Hyperphagia
How Investors May Respond To Soleno Therapeutics (SLNO) Legal Scrutiny After Accelerated Buyback
Simply Wall St.  ·  11-18
How Investors May Respond To Soleno Therapeutics (SLNO) Legal Scrutiny After Accelerated Buyback
Soleno Therapeutics Files Initial Beneficial Ownership Statement for Chief Development Officer Manher Joshi
Reuters  ·  11-13
Soleno Therapeutics Files Initial Beneficial Ownership Statement for Chief Development Officer Manher Joshi
Soleno Therapeutics Shares Rise 5.5% After $100 Million Share Repurchase Program
THOMSON REUTERS  ·  11-11
Soleno Therapeutics Shares Rise 5.5% After $100 Million Share Repurchase Program
BUZZ-U.S. STOCKS ON THE MOVE-Nebius, Estee Lauder, Soleno
Reuters  ·  11-11
BUZZ-U.S. STOCKS ON THE MOVE-Nebius, Estee Lauder, Soleno
Soleno Therapeutics Shares Rise 8.4% Premarket After Co Announces Entry Into $100 Mln Accelerated Share Repurchase Agreement
THOMSON REUTERS  ·  11-11
Soleno Therapeutics Shares Rise 8.4% Premarket After Co Announces Entry Into $100 Mln Accelerated Share Repurchase Agreement
Soleno Therapeutics Signs $100 Million Accelerated Share Repurchase Deal; Shares Up Pre-Bell
MT Newswires Live  ·  11-11
Soleno Therapeutics Signs $100 Million Accelerated Share Repurchase Deal; Shares Up Pre-Bell
Stock Track | Soleno Therapeutics Soars 5.70% Pre-market on $100 Million Share Repurchase Agreement
Stock Track  ·  11-11
Stock Track | Soleno Therapeutics Soars 5.70% Pre-market on $100 Million Share Repurchase Agreement
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement
THOMSON REUTERS  ·  11-11
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement
Stock Track | Soleno Therapeutics Plummets 5.44% Pre-Market on New Financial Risk Disclosure
Stock Track  ·  11-06
Stock Track | Soleno Therapeutics Plummets 5.44% Pre-Market on New Financial Risk Disclosure
Soleno Therapeutics’ Financial Challenges: Navigating Risks in VYKAT XR Commercialization
TIPRANKS  ·  11-06
Soleno Therapeutics’ Financial Challenges: Navigating Risks in VYKAT XR Commercialization
Soleno Therapeutics falls -29.0%
TIPRANKS  ·  11-06
Soleno Therapeutics falls -29.0%
Soleno Therapeutics Down Over 29%, on Pace for Largest Percent Decrease Since March 2021 -- Data Talk
Dow Jones  ·  11-06
Soleno Therapeutics Down Over 29%, on Pace for Largest Percent Decrease Since March 2021 -- Data Talk
Cantor Fitzgerald Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)
TIPRANKS  ·  11-05
Cantor Fitzgerald Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

Introduction

Company Name.
Soleno Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Issue price:
--